Regenesis Biomedical Names Scott Brooks Chief Executive Officer Former COO to Focus on Enhancing Clinical Adoption, Increasing Commercial Payer Reimbursement and Accelerating Growth
SCOTTSDALE, Ariz., May 14, 2013 /PRNewswire/ -- Regenesis Biomedical, Inc., a medical technology company focused on tissue regeneration, announced today that the Board of Directors has unanimously elected Scott Brooks as the next Chief Executive Officer (CEO), and member of the Board of Directors, succeeding Virginia Rybski. Brooks will assume his new role immediately.
Brooks, Regenesis' Chief Operating Officer since January 2012, will become the fourth CEO in Regenesis' history. Virginia Rybski, previous CEO, recently lost her battle with pancreatic cancer.
"After a thorough and deliberate selection process last year for the newly created COO position, the Board of Directors is delighted that Brooks will lead Regenesis as we finalize plans for clinical trials and expand reimbursement coverage," said John Voris, Chairman of the Board of Directors. "His knowledge and understanding of the issues important to our growth and value creation will ensure our continued success."
Scott Brooks' career spans senior management positions in BSN medical, KCI, Hill-Rom Company and Kimberly-Clark Healthcare, across sales and marketing, business development, national accounts and operations. He holds a Bachelor of Arts degree in Business Administration with emphasis in marketing from Western Washington University. He also is a graduate of the Looking Glass Experience conducted by the Center for Creative Leadership. In addition, he attended the executive management program at the University of Michigan Graduate School of Business. As a seasoned executive, Mr. Brooks brings not only impressive experience, but also a new and energizing vision for Regenesis. He possesses broad knowledge of the health care industry including many contacts with key thought-leaders in the industry. Scott is also a former executive committee member of the Federation of American Hospital Systems and was on the board at the American College of Phlebology Foundation.
"I look forward to leading Regenesis and our fantastic team of dedicated colleagues. With our innovative device, excellent sales and marketing organization, customer focused support team and close client relationships, we can expand our therapeutic relief to many of the millions of pain suffers in the U.S. and abroad," says CEO elect Scott Brooks. "As we continue to add to the clinical body of evidence for Provant Therapy, I am convinced we will deliver on our long term growth targets in the coming years. I am also pleased that the current senior management team will continue in the new leadership structure."
Regenesis has treated over 8,000 patients and attained greater than a 97% patient satisfaction score. Provant Therapy is an innovative medical device that delivers pulsed electromagnetic therapy at home. This non-narcotic pain relief is proven to be safe, easy to use and effective. Since 2003, the company has delivered average annual growth rates of 11-12%.
About Regenesis Biomedical
Regenesis Biomedical, Inc. is a privately held medical technology company focused on developing and marketing noninvasive regenerative medicine products. Regenesis developed, patented, and now markets the Provant Therapy System. Our customers include health care facilities, acute care hospitals, long-term acute care hospitals, skilled nursing facilities, rehabilitation centers, home health care agencies, and outpatient clinics.
About the Provant® Therapy System
Provant uses pulsed radio frequency energy (PRFE) to facilitate reduction of the pain and edema associated with post-operative, superficial soft tissues.
Contact: Regenesis Biomedical, Inc.
Scott Robey, Vice President Marketing
SOURCE Regenesis Biomedical, Inc.